Patents by Inventor Véronique Guillemard

Véronique Guillemard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGONISTIC ANTIBODIES TO TRKC RECEPTORS AND USES THEREOF
    Publication number: 20160130363
    Abstract: There are provided herein novel monoclonal antibodies that selectively bind and/or activate TrkC receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of TrkC, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the TrkC receptor.
    Type: Application
    Filed: October 27, 2015
    Publication date: May 12, 2016
    Inventors: Horacio Uri Saragovi, Veronique Guillemard, Neil Cashman
  • Agonistic antibodies to TrkC receptors and uses thereof
    Patent number: 9200080
    Abstract: There are provided herein novel monoclonal antibodies that selectively bind and/or activate TrkC receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of TrkC, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the TrkC receptor.
    Type: Grant
    Filed: November 30, 2010
    Date of Patent: December 1, 2015
    Inventors: Horacio Uri Saragovi, Véronique Guillemard, Neil Cashman
  • AGONISTIC ANTIBODIES TO TRKC RECEPTORS AND USES THEREOF
    Publication number: 20140004119
    Abstract: There are provided herein novel monoclonal antibodies that selectively bind and/or activate TrkC receptors, pharmaceutical compositions thereof and the use thereof for treating or preventing conditions which require activation of TrkC, such as amyotrophic lateral sclerosis and other neurodegenerative conditions and motor neuron diseases. The monoclonal antibodies are useful to screen for agents that share the same binding epitope on the TrkC receptor.
    Type: Application
    Filed: November 30, 2010
    Publication date: January 2, 2014
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIVERSITY
    Inventors: Horacio Uri Saragovi, Véronique Guillemard, Neil Cashman
  • Compound targeted for specific cells with reduced systemic toxicity
    Publication number: 20040115209
    Abstract: The present invention relates to a compound to selectively kill or protect a target cell in a patient with reduced systemic toxicity, which comprises a compound of the formula: W-Z-X wherein, X is a toxic agent or protective agent; W is a biologically active molecule which is adapted to selectively bind the target cell directly or indirectly; and Z is a breakable linker which covalently links W and X together, wherein the linked W remains bioavailable and bioactive, whereby the breakable linker releases the toxic agent or protective agent into the cell.
    Type: Application
    Filed: June 20, 2003
    Publication date: June 17, 2004
    Inventors: Uri H. Saragovi, Veronique Guillemard